

No difference in clinical outcome has been yet been reported between biclonal and monoclonal gammopathies.⁴ However, recognition and measurement of both clonal proteins during follow up helps in assessing treatment response and deciding further treatment.

REFERENCES:

1. Munshi NC, Longo DN, Anderson KC. Plasma cell disorders. In:Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, et al, editors. Harrison's principles of internal medicine. 19th ed. New York: McGraw Hill; 2015.
2. Kyle RA, Robinson R, Katzman J. The clinical aspects of biclonal gammopathies. Am J Med. 1981;71:999–1006.
3. Kim NY, Gong SJ, Kim J, Youn SM, Lee JA. Multiple myeloma with biclonal gammopathy accompanied by prostate cancer. Korean J Lab Med. 2011;31(4):285–89.
4. Kyle RA, Robinson RA, Katzmann JA. The clinical aspects of biclonal gammopathies. Review of 57 cases. Am J Med. 1981;71:999–1008. doi: 10.1016/0002-9343(81)90326-0.